Novo Nordisk raises profit forecast following Wegovy success
Pharmaceutical manufacturer Novo Nordisk has raised its annual profit forecast following strong sales figures for the weight-loss medication Wegovy in the USA. The company now expects a decline in adjusted revenues and profits of 4-12% instead of the previous forecast of 5% or more decline. The weight-loss medication Wegovy is proving to be a major sales success.